ArticleFrontiers in pediatrics2025
Pediatric liver transplant for maple syrup urine disease a single center experience.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Maple syrup urine disease (MSUD) is an autosomal recessive inborn error of branched-chain amino acid metabolism caused by an inherited deficiency of branched-chain alpha-ketoacid dehydrogenase (BCKDH) activity that degrades isoleucine, leucine, and valine. Liver transplantation (LT) is a therapeutic option to treat the classical severe type of MSUD. This study aimed to assess and compare liver biochemical outcomes and amino BCAAs levels post-LT according to different types of donors. Methods: Retrospective cohort analysis of 10 patient medical records diagnosed as MSUD who underwent LT in King Fahad Specialist Hospital-Dammam between January 2013 and May 2023. Results: Ten pediatric patients diagnosed with MSUD who had finished 1 year of follow-up after LT were included in the study. The median age of diagnosis among the pediatric patients was 1 month (as it is included in the national neonatal screening). Besides, the median age for LT was 123 months (10 years 3 months) (with a range of 9-173 months). Availability of milk formula, prevention of further neurological insult, and difficulty in controlling the protein intake were the main indications for LT. Post LT, six patients (60%) were immediately initiated on a regular diet, and four patients (40%) waited for 3 months before starting a regular diet. All the patients were on Tacrolimus as immunosuppression, with three patients started on Mycophenolate because of biopsy-proven acute cellular rejection. Our result showed 100% 1-year graft survival and 100% until the time of report, with no donor complications. 70% of the explanted liver had been re-transplanted as a domino liver transplant. No clinical or laboratory difference when comparing living-related to living-unrelated or deceased donor liver transplant. 100% of our patients and families showed satisfaction with the decision of liver transplant. Conclusion: MSUD post liver transplant showed a 100% graft survival rate, and all patients and families showed satisfaction. In settings with limited deceased donor organs, living-related donor LT (even from heterozygous carriers) is a viable option for MSUD, yielding comparable metabolic control and graft outcomes to other donor types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.